Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers ...
Improving hospital arrival times for AIS in patients with T2D is cost-effective, but primary prevention yields greater benefits.
Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.
The EPA said last Monday it wants to roll back some regulations on "forever chemicals" in drinking water put into place in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results